NCT01041092View on ClinicalTrials.gov

Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Schizophrenia
Interventions
DRUG

raloxifene

Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.

Trial Locations (1)

Unknown

Fundació Sant Joan de Déu, Esplugues de Llobregat

All Listed Sponsors
lead

Fundació Sant Joan de Déu

OTHER

NCT01041092 - Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women | Biotech Hunter | Biotech Hunter